Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ (SBECD-enabled fosphenytoin)
Ligand Pharmaceuticals Incorporated announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U.S. Food and Drug Administration
Category: Drug delivery
Lilly’s baricitinib/remdesivir combo lowers recovery time in hospitalised COVID-19 patients
Eli Lilly has unveiled promising new data from a study investigating the efficacy of baricitinib when combined with with Gilead’s
U.S. FDA Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19
— Veklury Is First and Only FDA-Approved Treatment for COVID-19 in the United States — — Veklury Shortened Time to
Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing
Remdesivir, an investigational broad-spectrum antiviral agent, formulated with sulfobutyl beta-cyclodextrin, has shown in vitro activity against SARSCoV-2. Currently, remdesivir is
Results of HPBCD-enabled MTX110 Phase I Study
Midatech Pharma PLC, an R&D biotechnology company focused on improving the bio‐delivery and biodistribution of medicines, announced encouraging headline results
Gilead debates WHO results on low effectivity of remdesivir in Covid-19 mortality rate
Pharmafile reports that Gilead’s antiviral therapy remdesivir has emerged as one of the most promising drugs to treat COVID-19 infections,
COVID-19 is Less Frequent at High Altitude Under Hypobaric conditions: The South-American Experience
As a cyclodextrin (SBECD) is used in one of the most potent drug formulation against Covid-19 the readers of the
International E-Conference on Pharmacology & Toxicology
International E-Conference on Pharmacology & Toxicology will be held on December 1-2, 2020. This conference will cover a wide spectrum of
Combined therapy (remdesivir, dexamethasone and monoclonal antibodies) for the treatment of President Trump
Science News reported on October 5, 2020 the opinion of Rajesh Gandhi, an infectious diseases physician at Massachusetts General Hospital
Nasal administration of COVID-19 vaccine
Researchers lead by Professor Michael S. Diamond at Washington University School of Medicine in St. Louis, have developed a COVID-19